NCT02573259 · OUTCOME

Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors · Source last updated 2021-12-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

What was measured

Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

Analysis population: Analysis population included all enrolled participants who received at least 1 dose of study medication.

Groups in this outcome

Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])

Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)

Part 1: PF-06801591 1 mg/kg (IV)

Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)

Part 1: PF-06801591 3 mg/kg (IV)

Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)

Part 1: PF-06801591 10 mg/kg (IV)

Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)

Part 1: PF-06801591 300 mg (Subcutaneously [SC])

Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)

Part 2: PF-06801591 300 mg (SC) for NSCLC

Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)

Part 2: PF-06801591 300 mg (SC) for UC

Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Reported measurements

ANEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	16	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	6	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	38	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	16	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	9	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	7	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

HEMOGLOBIN INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	60	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	35	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

LYMPHOCYTE COUNT DECREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	9	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	27	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	20	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	21	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	11	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	5	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

LYMPHOCYTE COUNT INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	14	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	63	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	37	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

NEUTROPHIL COUNT DECREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	61	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	35	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

PLATELET COUNT DECREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	12	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	56	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	33	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	12	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	5	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

WHITE BLOOD CELL DECREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	10	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	62	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	34	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

ALANINE AMINOTRANSFERASE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	14	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	45	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	31	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	19	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

ALKALINE PHOSPHATASE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	6	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	36	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	21	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	22	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	11	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	4	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

ASPARTATE AMINOTRANSFERASE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	67
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	11	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	44	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	23	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	17	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	13	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

BLOOD BILIRUBIN INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	58	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	34	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	6	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

CPK INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0
Part 1: PF-06801591 1 mg/kg (IV)	0
Part 1: PF-06801591 3 mg/kg (IV)	0
Part 1: PF-06801591 10 mg/kg (IV)	0
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0
Part 2: PF-06801591 300 mg (SC) for NSCLC	3
Part 2: PF-06801591 300 mg (SC) for UC	0

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported

CREATININE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	58	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	6	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	30	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	5	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

GGT INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1
Part 1: PF-06801591 1 mg/kg (IV)	0
Part 1: PF-06801591 3 mg/kg (IV)	0
Part 1: PF-06801591 10 mg/kg (IV)	0
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0
Part 2: PF-06801591 300 mg (SC) for NSCLC	4
Part 2: PF-06801591 300 mg (SC) for UC	2

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPERCALCEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	51	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	31	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	5	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

HYPERGLYCEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	14	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	24	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	12	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	31	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	21	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	10	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	4	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

HYPERKALEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	48	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	27	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	6	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	11	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPERMAGNESEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	55	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	35	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	6	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPERNATREMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	51	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	35	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

HYPOALBUMINEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	10	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	40	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	23	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	18	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	11	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	10	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	4	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

HYPOCALCEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	49	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	30	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	12	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	7	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

HYPOGLYCEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	8	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	60	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	32	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	6	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPOKALEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	10	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	61	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	33	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPOMAGNESEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	42	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	29	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	14	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	8	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

HYPONATREMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	8	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	45	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	25	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	19	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	10	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

HYPOPHOSPHATEMIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	67
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	56	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	27	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	7	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	7	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	4	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

LIPASE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	37

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	50	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	23	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	11	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	7	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	2	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

SERUM AMYLASE INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	7	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	13	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	45	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	23	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	16	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	10	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	2	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

PROTEINURIA

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	6
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	66
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	9	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	46	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	15	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	6	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	15	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	17	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	5	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	5	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	Not reported	Not reported	Not reported	Not reported

ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	38

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	11	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	44	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	19	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	19	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	15	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	4	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	3	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

INR INCREASED

Analysis denominator · Participants

Group	Source count
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2
Part 1: PF-06801591 1 mg/kg (IV)	7
Part 1: PF-06801591 3 mg/kg (IV)	8
Part 1: PF-06801591 10 mg/kg (IV)	7
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	15
Part 2: PF-06801591 300 mg (SC) for NSCLC	68
Part 2: PF-06801591 300 mg (SC) for UC	36

Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	5	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	6	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	4	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	12	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	39	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	31	Not reported	Not reported	Not reported	Not reported

Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	2	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	3	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	25	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	4	Not reported	Not reported	Not reported	Not reported

Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	1	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	1	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	1	Not reported	Not reported	Not reported	Not reported

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 1 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 3 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 10 mg/kg (IV)	0	Not reported	Not reported	Not reported	Not reported
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	0	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for NSCLC	3	Not reported	Not reported	Not reported	Not reported
Part 2: PF-06801591 300 mg (SC) for UC	0	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 1 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 3 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 10 mg/kg (IV)	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 1: PF-06801591 300 mg (Subcutaneously [SC])	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for NSCLC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.
Part 2: PF-06801591 300 mg (SC) for UC	NA	Not reported	Not reported	Not reported	CTCAE grade not defined.

Complete source fields

classes

categories
measurements
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
16
group Id
OG006
value
6
title
Grade 0
measurements
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
4
group Id
OG003
value
5
group Id
OG004
value
5
group Id
OG005
value
38
group Id
OG006
value
16
title
Grade 1
measurements
group Id
OG000
value
1
group Id
OG001
value
4
group Id
OG002
value
3
group Id
OG003
value
1
group Id
OG004
value
8
group Id
OG005
value
13
group Id
OG006
value
9
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
1
group Id
OG006
value
7
title
Grade 3
measurements
comment
CTCAE grade not defined.
group Id
OG000
value
NA
comment
CTCAE grade not defined.
group Id
OG001
value
NA
comment
CTCAE grade not defined.
group Id
OG002
value
NA
comment
CTCAE grade not defined.
group Id
OG003
value
NA
comment
CTCAE grade not defined.
group Id
OG004
value
NA
comment
CTCAE grade not defined.
group Id
OG005
value
NA
comment
CTCAE grade not defined.
group Id
OG006
value
NA
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
ANEMIA
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
60
group Id
OG006
value
35
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
7
group Id
OG006
value
3
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 3
measurements
comment
CTCAE grade not defined.
group Id
OG000
value
NA
comment
CTCAE grade not defined.
group Id
OG001
value
NA
comment
CTCAE grade not defined.
group Id
OG002
value
NA
comment
CTCAE grade not defined.
group Id
OG003
value
NA
comment
CTCAE grade not defined.
group Id
OG004
value
NA
comment
CTCAE grade not defined.
group Id
OG005
value
NA
comment
CTCAE grade not defined.
group Id
OG006
value
NA
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
HEMOGLOBIN INCREASED
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
3
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
9
group Id
OG005
value
27
group Id
OG006
value
20
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
2
group Id
OG003
value
1
group Id
OG004
value
2
group Id
OG005
value
21
group Id
OG006
value
11
title
Grade 1
measurements
group Id
OG000
value
2
group Id
OG001
value
2
group Id
OG002
value
6
group Id
OG003
value
4
group Id
OG004
value
1
group Id
OG005
value
15
group Id
OG006
value
5
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
3
group Id
OG005
value
5
group Id
OG006
value
2
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
LYMPHOCYTE COUNT DECREASED
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
14
group Id
OG005
value
63
group Id
OG006
value
37
title
Grade 0
measurements
comment
CTCAE grade not defined.
group Id
OG000
value
NA
comment
CTCAE grade not defined.
group Id
OG001
value
NA
comment
CTCAE grade not defined.
group Id
OG002
value
NA
comment
CTCAE grade not defined.
group Id
OG003
value
NA
comment
CTCAE grade not defined.
group Id
OG004
value
NA
comment
CTCAE grade not defined.
group Id
OG005
value
NA
comment
CTCAE grade not defined.
group Id
OG006
value
NA
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
5
group Id
OG006
value
1
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 3
measurements
comment
CTCAE grade not defined.
group Id
OG000
value
NA
comment
CTCAE grade not defined.
group Id
OG001
value
NA
comment
CTCAE grade not defined.
group Id
OG002
value
NA
comment
CTCAE grade not defined.
group Id
OG003
value
NA
comment
CTCAE grade not defined.
group Id
OG004
value
NA
comment
CTCAE grade not defined.
group Id
OG005
value
NA
comment
CTCAE grade not defined.
group Id
OG006
value
NA
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
LYMPHOCYTE COUNT INCREASED
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
6
group Id
OG002
value
7
group Id
OG003
value
5
group Id
OG004
value
13
group Id
OG005
value
61
group Id
OG006
value
35
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
2
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
0
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
2
group Id
OG006
value
3
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
NEUTROPHIL COUNT DECREASED
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
7
group Id
OG002
value
7
group Id
OG003
value
6
group Id
OG004
value
12
group Id
OG005
value
56
group Id
OG006
value
33
title
Grade 0
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
3
group Id
OG005
value
12
group Id
OG006
value
5
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
PLATELET COUNT DECREASED
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
5
group Id
OG002
value
5
group Id
OG003
value
3
group Id
OG004
value
10
group Id
OG005
value
62
group Id
OG006
value
34
title
Grade 0
measurements
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
3
group Id
OG003
value
4
group Id
OG004
value
4
group Id
OG005
value
5
group Id
OG006
value
3
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
0
group Id
OG006
value
1
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
WHITE BLOOD CELL DECREASED
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
4
group Id
OG004
value
14
group Id
OG005
value
45
group Id
OG006
value
31
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
3
group Id
OG004
value
1
group Id
OG005
value
19
group Id
OG006
value
3
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
3
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
3
group Id
OG006
value
1
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
ALANINE AMINOTRANSFERASE INCREASED
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
4
group Id
OG002
value
5
group Id
OG003
value
4
group Id
OG004
value
6
group Id
OG005
value
36
group Id
OG006
value
21
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
2
group Id
OG002
value
3
group Id
OG003
value
2
group Id
OG004
value
7
group Id
OG005
value
22
group Id
OG006
value
11
title
Grade 1
measurements
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
2
group Id
OG005
value
7
group Id
OG006
value
4
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
3
group Id
OG006
value
2
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
ALKALINE PHOSPHATASE INCREASED
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
5
group Id
OG002
value
7
group Id
OG003
value
5
group Id
OG004
value
11
group Id
OG005
value
44
group Id
OG006
value
23
title
Grade 0
measurements
group Id
OG000
value
2
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
4
group Id
OG005
value
17
group Id
OG006
value
13
title
Grade 1
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
5
group Id
OG006
value
1
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
1
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
67
group Id
OG006
value
38
units
Participants
title
ASPARTATE AMINOTRANSFERASE INCREASED
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
7
group Id
OG002
value
7
group Id
OG003
value
6
group Id
OG004
value
13
group Id
OG005
value
58
group Id
OG006
value
34
title
Grade 0
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
6
group Id
OG006
value
3
title
Grade 1
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
1
title
Grade 2
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
title
Grade 3
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants
title
BLOOD BILIRUBIN INCREASED
categories
measurements
group Id
OG005
value
3
title
Grade 0
measurements
group Id
OG005
value
0
title
Grade 1
measurements
group Id
OG005
value
0
title
Grade 2
measurements
group Id
OG005
value
0
title
Grade 3
measurements
group Id
OG005
value
0
title
Grade 4
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
3
group Id
OG006
value
0
units
Participants
title
CPK INCREASED

denoms

counts
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
8
group Id
OG003
value
7
group Id
OG004
value
15
group Id
OG005
value
68
group Id
OG006
value
38
units
Participants

description

groups

description
Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)
id
OG000
title
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])
description
Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)
id
OG001
title
Part 1: PF-06801591 1 mg/kg (IV)
description
Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)
id
OG002
title
Part 1: PF-06801591 3 mg/kg (IV)
description
Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)
id
OG003
title
Part 1: PF-06801591 10 mg/kg (IV)
description
Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)
id
OG004
title
Part 1: PF-06801591 300 mg (Subcutaneously [SC])
description
Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)
id
OG005
title
Part 2: PF-06801591 300 mg (SC) for NSCLC
description
Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)
id
OG006
title
Part 2: PF-06801591 300 mg (SC) for UC

param Type

COUNT_OF_PARTICIPANTS

population Description

Analysis population included all enrolled participants who received at least 1 dose of study medication.

reporting Status

POSTED

time Frame

Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

title

Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice